Nummular Eczema Clinical Trials

Find Nummular Eczema Clinical Trials Near You

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema Who Are Not Adequately Controlled With Topical Corticosteroids or When This Treatment is Not Medically Advisable (LUMINE)

Status: Recruiting
Location: See location...
Intervention Type: Drug, Other
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Participants eligible for inclusion in this trial must fulfil all inclusion criteria per protocol, main criteria are listed below:

• Ability to understand the purpose and risks of the trial, willingness and ability to comply with the protocol, and ability to provide written informed consent in accordance with institutional and regulatory guidelines.

• Adult (aged 18 years or more at the time of Screening) diagnosed clinically with NE, as confirmed by the Investigator.

• Presence of nummular eczema signs and/or symptoms for at least 6 months prior to Screening.

• Investigator Global Assessment score \>=3 at both Screening and Baseline/Day 1 visits.

• In the judgement of the Investigator, having inadequate response to TCS.

Locations
Other Locations
Germany
Alm Site 1
RECRUITING
Freiburg Im Breisgau
Contact Information
Primary
Estrella Garcia
gco@almirall.com
+34620985953
Backup
Natalia Calderón
gco@almirall.com
Time Frame
Start Date: 2026-04-24
Estimated Completion Date: 2029-02
Participants
Target number of participants: 270
Treatments
Experimental: Placebo-controlled Period: Lebrikizumab
Placebo_comparator: Placebo-controlled Period: Placebo
Experimental: Blinded Extension Period: Lebrikizumab
Experimental: Blinded Extension Period: Lebrikizumab + Placebo
Related Therapeutic Areas
Sponsors
Leads: Almirall, S.A.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.